Dose reductions of vincristine in children with medulloblastoma treated in the maintenance arm of the prospective multicenter trial HIT'91.
von Bueren
A O
AO
von Hoff
K
K
Benesch
M
M
Rutkowski
S
S
D000293:Adolescent; D000367:Age Factors; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity*; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage / Q000633:toxicity; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D020360:Neoadjuvant Therapy; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D014750:Vincristine / Q000008:administration & dosage* / Q000633:toxicity*
D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D008130:Lomustine; D002945:Cisplatin